SECOND OPINION: BIG PHARMA’S OUT-OF-POCKET PLANS ON BRAND NAME INHALERS MAY BE DESIGNED TO FURTHER UNDERMINE COMPETITION
Big Pharma’s Announcements Designed to Deflect from Criticism and Scrutiny for Years of Egregious Anti-Competitive and Pricing Practices on Brand Name Inhalers Under increasing scrutiny from policymakers and the public for egregious anti-competitive and price-gouging practices on brand name inhalers, several Big Pharma companies, including AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline (GSK), recently announced commitments to
0 CommentsComment on Facebook